{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:05:21Z","timestamp":1790111121899,"version":"4.0.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jcf.2026.06.008","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T20:54:23Z","timestamp":1782939263000},"page":"813-816","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hepatic steatosis in adults on CFTR modulators is commonly associated with cardiometabolic criteria consistent with metabolic dysfunction-associated steatotic liver disease"],"prefix":"10.1016","volume":"25","author":[{"given":"Sofia","family":"Manioudaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7926-3062","authenticated-orcid":false,"given":"Larisa","family":"Vasilieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Geladari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9971-5174","authenticated-orcid":false,"given":"Iliana","family":"Mani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6725-3510","authenticated-orcid":false,"given":"Vasilios","family":"Sevastianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filia","family":"Diamantea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1991-7436","authenticated-orcid":false,"given":"Alexandra","family":"Alexopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcf.2026.06.008_bib0001","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/MPG.0000000000003944","article-title":"Towards a standardized classification of the hepatobiliary manifestations in cystic fibrosis (CFHBI): a joint ESPGHAN\/NASPGHAN position paper","volume":"78","author":"Bodewes","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jcf.2026.06.008_bib0002","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jhep.2021.09.042","article-title":"Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies","volume":"76","author":"Dana","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcf.2026.06.008_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.nut.2025.112984","article-title":"Nutritional outcomes in people with cystic fibrosis receiving elexacaftor\/tezacaftor\/ivacaftor: a 24-mo real-world study","volume":"142","author":"Alicandro","year":"2026","journal-title":"Nutrition"},{"issue":"4","key":"10.1016\/j.jcf.2026.06.008_bib0004","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/ncp.11332","article-title":"Evolving nutrition therapy in cystic fibrosis: Adapting to the CFTR modulator era","volume":"40","author":"Vavrina","year":"2025","journal-title":"Nutr Clin Pract"},{"key":"10.1016\/j.jcf.2026.06.008_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.nut.2024.112425","article-title":"Impact of CFTR modulator therapy on body composition as assessed by thoracic computed tomography: a follow-up study","volume":"123","author":"Navas-Moreno","year":"2024","journal-title":"Nutrition"},{"issue":"3","key":"10.1016\/j.jcf.2026.06.008_bib0006","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jcf.2026.06.008_bib0007","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16127","article-title":"Accuracy of non-invasive imaging techniques for the diagnosis of MASH in patients with MASLD: a systematic review","volume":"45","author":"Cathcart","year":"2025","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.jcf.2026.06.008_bib0008","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jcf.2025.02.007","article-title":"Non-invasive evaluation of steatosis and fibrosis in the liver in adults patients living with cystic fibrosis","volume":"24","author":"Pi\u00f1ar-Guti\u00e9rrez","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2026.06.008_bib0009","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","article-title":"Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis","volume":"66","author":"Karlas","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcf.2026.06.008_bib0010","article-title":"Head-to-head comparison between vibration-controlled transient elastography and histology in predicting liver-related events due to metabolic dysfunction-associated steatotic liver disease","author":"Zhang","year":"2025","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jcf.2026.06.008_bib0011","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/hep.29217","article-title":"Adult-onset cystic fibrosis liver disease: Diagnosis and characterization of an underappreciated entity","volume":"66","author":"Koh","year":"2017","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jcf.2026.06.008_bib0012","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2468-1253(19)30419-4","article-title":"Prevalence of steatosis and fibrosis in young adults in the UK: a population-based study","volume":"5","author":"Abeysekera","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jcf.2026.06.008_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2026.04.002","article-title":"Lack of clinical change in longitudinal vibration controlled transient elastography among children with cystic fibrosis and poor association with non-invasive biomarkers of liver disease","author":"Ye","year":"2026","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2026.06.008_bib0014","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jcf.2026.06.008_bib0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4254\/wjh.v10.i1.34","article-title":"Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease","volume":"10","author":"Ayoub","year":"2018","journal-title":"World J Hepatol"},{"issue":"4","key":"10.1016\/j.jcf.2026.06.008_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2023.166662","article-title":"Pharmacological inhibition of CFTR attenuates nonalcoholic steatohepatitis (NASH) progression in mice","volume":"1869","author":"Rajak","year":"2023","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"2","key":"10.1016\/j.jcf.2026.06.008_bib0017","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1569-1993(02)00031-0","article-title":"Optimising nutrition in cystic fibrosis","volume":"1","author":"Bell","year":"2002","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326016498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326016498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:07:28Z","timestamp":1790107648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326016498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1569199326016498"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.06.008","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatic steatosis in adults on CFTR modulators is commonly associated with cardiometabolic criteria consistent with metabolic dysfunction-associated steatotic liver disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}